VeriSIM Life partnered with our client to translate drug candidates targeting SUD patient therapies more rapidly and accurately than traditional methods that depend on the experimental uncertainty of modeling for data.
Artificial intelligence in drug development has transformative potential when it comes to pharma research and development (R&D). Download the white paper to advance the adoption of AI within your organization.
Frost & Sullivan 2022 Competitive Strategy Leader Award North American Artificial Intelligence Enabled Preclinical Development Industry
This study covers one of the many applications of BIOiSIM. Our aim was to establish what the pharmacokinetic (PK) profile would look like in the different subjects studied.
This white paper showcases how fusing artificial intelligence and mechanistic modeling can be used to accurately predict the disposition of small molecules across different subjects for translation to clinical success.